ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GOVXW GeoVax Labs Inc

0.081
0.0278 (52.26%)
Last Updated: 19:59:45
Delayed by 15 minutes
Name Symbol Market Type
GeoVax Labs Inc NASDAQ:GOVXW NASDAQ Equity Warrant
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.0278 52.26% 0.081 0.082 0.09 0.60 0.0606 0.22 515,193 19:59:45

GeoVax to Present at the 36th Annual Roth Conference

12/03/2024 1:00pm

GlobeNewswire Inc.


GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more GeoVax Labs Charts.

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024.

Presentation Details:

Presenter:       David Dodd, Chairman & CEODate/Time:      March 18, 2024, 2:30 pm PTLocation:         Dana Point, CAWebcast Link: Roth Conference Webcast

The Company will also host in-person investor meetings.  Institutional investors wishing to attend the conference and schedule meetings with GeoVax leadership should contact their Roth MKM representative.

About GeoVaxGeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Company Contact: Investor Relations Contact: Media Contact:
info@geovax.com paige.kelly@sternir.com sr@roberts-communications.com 
678-384-7220 212-698-8699 202-779-0929

1 Year GeoVax Labs Chart

1 Year GeoVax Labs Chart

1 Month GeoVax Labs Chart

1 Month GeoVax Labs Chart

Your Recent History

Delayed Upgrade Clock